SOLICITATION NOTICE
65 -- ME-1111-08_Casting Splints - Technical Requirement Responses
- Notice Date
- 5/11/2012
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 423450
— Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
- Contracting Office
- Defense Logistics Agency, DLA Acquisition Locations, DLA Troop Support - Medical, 700 Robbins Avenue, Philadelphia, Pennsylvania, 19111-5096, United States
- ZIP Code
- 19111-5096
- Solicitation Number
- ME-1111-08_Casting_Splints
- Point of Contact
- Robert Halliday, Phone: 011-49-6221-172109, Thomas Winkel, Phone: 011-49-6221-172106
- E-Mail Address
-
Robert.halliday@us.army.mil, tom.winkel@us.army.mil
(Robert.halliday@us.army.mil, tom.winkel@us.army.mil)
- Small Business Set-Aside
- N/A
- Description
- Use this document for your response to the Technical Requirements for this RFIAQ. Fill in the attachment and provide with your initial submittal to this FBO RFIAQ. *A vendor who does not meet these requirements or who does not submit documentation to support these requirements with initial submittal will be disqualified in Phase I. *Vendor who does not meet the deadline of COB on the date/time listed in the FBO will be disqualified from further consideration in the standardization initiative. *Please remember to attach your product literature and catalogs required in the Federal Business Opportunity. The Defense Medical Materiel Program Office (DMMPO) announces a Request for Incentive Agreement Quotation (RFIAQ) for the standardization of Casting Splints. The Medical Materiel Enterprise Standardization Office (MMESO) Europe is the lead MMESO for this project. The primary objective of this effort is to standardize the quality of care across the Military Treatment Facilities (MTFs) and operational assemblages based on the critical balance of clinical efficacy and value. The intent for this initiative is the standardization of a clinically preferred product(s) and source for institutional and operational medicine requirements at the best price for each MMESO Area of Responsibility (AOR). It is also intended for this initiative to result in the reduction of Stock Keeping Units (SKUs) and National Stock Numbers (NSN). Standardized products must be obtained through the Department of Defense (DoD) Prime Vendor (PV) Program. As an enterprise-wide clinically driven program, vendors and products must meet specific technical requirements plus products must meet or exceed specific clinical performance expectations as a primary consideration. Among vendors who meet the technical requirements and the products that meet or exceed the clinical acceptability, then clinically preferred, best value will determine selection for each MMESO AOR. It is intended that the selected standardized vendor(s) for this Standardization Action (SA) support the enterprise goal of medical materiel standardization that combines operational and institutional requirements. Vendor is not required to quote for each MMESO AOR. The Government will make a single selection for each of the following MMESO AORs: 1. MMESO North 2. MMESO South 3. MMESO West 4. MMESO Pacific 5. MMESO Europe The major facilities in the MMESOs include but are not limited to MMESO North: Walter Reed National Military Medical Center, Naval Medical Center Portsmouth, Wright-Patterson Medical Center; MMESO South: Wilford Hall Ambulatory Surgical Center, Brooke Army Medical Center, Naval Hospital Jacksonville, Martin Army Community Hospital; MMESO West: Naval Medical Center San Diego, Madigan Army Medical Center, Irwin Army Community Hospital, Mike O'Callaghan Federal Hospital; MMESO Pacific: Tripler Army Medical Center, Honolulu, HI, 18th Medical Group, Kadena AB, Okinawa, US Naval Hospital, Yokosuka, Japan; MMESO Europe: Landstuhl Regional Medical Center, Landstuhl, GE, US Naval Hospital, Naples, Italy, the 48th Medical Group, Lakenheath, UK; and Operational U.S. Forces. This SA is part of the Medical/Surgical Prime Vendor program executed by the Defense Logistics Agency (DLA) Troop Support, Directorate of Medical Materiel. To participate in this SA your company must have or be in the process of obtaining a Distribution and Pricing Agreement (DAPA) and a separate commercial agreement with the current Med-Surg PV for each MMESO AOR for which a quote is submitted, i.e., Cardinal Health, and Owens & Minor. This requirement is pursuant to the DAPA clause by which DAPA holders agree to the standardization initiative and agree to allow PVs to distribute their products. The IA resulting from this RFIAQ is a supplement to the PV Program and is not a contract. For additional information regarding DLA Troop Support Medical's PV program please access its web site at https://www.medical.dla.mil/. This IA standardization initiative will be a Three Phase IPP Process: vendor(s) who meets the technical / company requirements in Phase I will be invited to participate in Phase II where no-charge products will be provided for clinical evaluation and Phase III where pricing will be required for submittal. Phase II and Phase III will be run concurrently. The resulting IA will be for a base period of two (2) years (24 months) from date of selection with three (3) 12-month "option" periods not to exceed a total of 5 years. Anticipated selection date is October 2012. The selection will be based on the product and vendor that provides the Best Value to the enterprise. Products and vendors that meet or exceed the technical and clinical performance requirements will be considered clinically preferred products and sources. Among vendors who meet the technical requirements and the products that meet or exceed the clinically preferred standard, best price (i.e. lowest Aggregate Post Standardization Cost) will determine selection for each MMESO AOR. Points of Contact: Mr. Robert Halliday, Clinical Analyst, Robert.halliday@us.army.mil 011-49-6221-172109, and Mr. Tom Winkel, Team Leader, Tom.winkel@us.army.mil 011-49-6221-172106. B. Products & Performance Required. The MMESOs are seeking product line items in the category of Casting Splints. Within the MMESOs this product line has an estimated annual dollar requirement of $687,099.59. This forecast is based on historical usage data during a recent 12-month period. Based on usage data, thirty three (33) of the total seventy one (71) line items represent the top eight (8) products and account for 79.04% ($543,037.71) of the total volume in sales $687,099.59 in the MMESOs and are clinically significant. Estimated annual demand per Area of Responsibility is approximately MMESO North $136,466.13, MMESO South $204,302.45, MMESO West $165,749.73, MMESO Europe $118,913.62, and MMESO Pacific $61,667.66. The top high volume usage lines for this project are shown in the Technical/Company Requirements below. C. Instructions to Vendors Vendors interested in participating in this standardization initiative will provide an initial response to the FBO-posted RFIAQ to Mr. Rob Halliday, Clinical Analyst, at robert.halliday@us.army.mil and Mr. Tom Winkel, Team Leader, Tom.winkel@us.army.mil. The vendor's initial responses will include detailed information requested in the technical/company requirements listed in the FBO RFIAQ and must also include: (1) Company name and address; (2) Company Point of Contact (POC) (Name and Phone Number, Fax Number, and E-mail address); and (3) Identification of the RFIAQ to which the vendor is responding. Due to the potential for email to be lost in transmission, from network security, etc., vendors are strongly encouraged to confirm with the MMESO Europe that their initial submissions, quote and literature arrived at the MMESO Europe via email. Each submitting vendor is advised to confirm receipt, allowing adequate time for resubmission before the due date / time, should a problem occur with the first submission. Vendor should complete and submit the attached document. A vendor, who cannot open the attachments, may contact the POC as noted in the FBO RFIAQ and a copy will be provided via an alternate method (fax, email or hard copy). Vendors that do not meet the deadline of 5:00 PM Eastern Standard Time (EST) on the date listed for closing will be disqualified from further consideration in the standardization initiative. D. Source Selection Procedures The MMESO Joint Product Review Board (JPRB) will serve as the forum for clinical recommendations for product selection, seeking and evaluating opportunities for committed volume purchase agreements, and coordinating logistics efforts in support of DoD Components. The boards are chaired by Designated Senior Logisticians (DSLs) and co-chaired by Designated Senior Clinicians (DSCs) in the MMESO AORs and include clinicians and logisticians for MTFs within each MMESO. The Clinical Advisory Committee (CAC) members are the deciding officials for this initiative. Vendor quotes should contain the vendor's best discounts off of the vendor's DAPA pricing for each MMESO AOR for which a quote is submitted based on committed volume of 80% of the total requirements of the MTFs in that MMESO AOR. The MMESO Europe reserves the right to conduct discussions and request revised quotes, if determined necessary. Phase I Technical/Company Evaluation The MMESO CPT will review the responses from the vendors and determine which vendors meet the technical/company requirements. A vendor must meet the technical requirements for continued consideration in this initiative. Failure to provide any requested information or meet any of the technical requirements will disqualify the vendor from further consideration. A vendor who meets the following technical/company requirements will be qualified and invited to participate in the clinical/performance selection process and will be requested to submit products for testing and their best price discount quotes via an e-mail communication. All communications of significant acquisition milestones (such as invitations to participate or notices of disqualification) should be digitally signed. Technical/Company Requirements During the pre-source selection procedures, the CPT approved the company/technical requirements outlined below. The requirements below must be answered with the vendor's initial submittal and required documents by the response date stated in the FBO announcement. A vendor who does not meet these requirements or who does not submit documentation to support these requirements with initial submittal will be disqualified in Phase I. 1. Vendor must provide a complete line of Casting Splints products. a. This product line, Casting Splints, latex-free/safe precut synthetic fiberglass splint material that incorporates padding and rolled synthetic fiberglass splint material that incorporates padding in a variety of sizes to include at a minimum the specific products listed. 1) Fiberglass/synthetic splint roll with padding 4 inches wide by 15 feet long 2) Fiberglass/synthetic splint roll with padding 3 inches wide by 15 feet long 3) Fiberglass/synthetic splint roll with padding 5 inches wide by 15 feet long 4) Fiberglass/synthetic splint roll with padding 2 inches wide by 15 feet long 5) Fiberglass/synthetic splint pre-cut with padding 3 inches wide by 35 inches long 6) Fiberglass/synthetic splint pre-cut with padding 3 inches wide by 12 inches long 7) Fiberglass/synthetic splint pre-cut with padding 4 inches wide by 15 inches long 8) Fiberglass/synthetic splint pre-cut with padding 5 inches wide by 30 inches long *Operational usage items are included in this list of Casting Splints. b. Vendor must provide a complete itemized list of products supplied (manufactured and/or distributed by brands and descriptions) via excel sheet, and product catalog & literature in response to this RFIAQ. Vendors are required to supply all items listed in all sizes and styles. 2. Vendors must provide supporting documentation that all products meet guidance set forth by the OSHA for the manufacturing of Orthopedic, Prosthetic, Surgical Appliances and Supplies used in manufacturing Casting Splints product items. 3. Vendor must provide documentation for the amount of time it takes for the casting splint material to set. 4. Vendor must have or be in the process of applying for a DAPA number for the Casting Splints. Vendor must provide the DAPA number or provide documentation of the DAPA number application date. 5. Vendor must have or be in the process of applying for agreements with the current Med/Surg Prime Vendors for each MMESO AOR for which a quote is submitted, i.e. Cardinal Health and Owens & Minor for Casting Splints. 6. Vendor will be required to submit discounts off of DAPA for all products included in this standardization initiative when pricing is requested in Phase III. Where lower FSS prices are available, DAPA holders are required by the terms of the DAPA to provide the FSS price as the DAPA price. A vendor shall not quote FSS prices as the discounted price for purposes of this standardization initiative. Vendor is not required to provide a quote for all MMESO AORs. A vendor who does not provide discounts off DAPA in Phase III for all products will be disqualified. 7. Vendor must indicate country from which each line item is an end product, IAW Trade Agreements Act and provide date last updated in the DAPA Management System. Vendors having existing DAPA numbers must also ensure that all DAPA line items/end products in the subject product line list the proper Trade Agreements Act country in the DAPA Management System. Vendors not compliant IAW Trade Agreements Act will be disqualified. 8. Vendor is advised that the Berry Amendment may apply to this SA, subject to the June 13, 2001 "Class Determination of Domestic Non-Availability for Defense Supply Center Philadelphia Medical/Surgical Prime Vendor Programs". 9. Vendors must identify with initial submittal for which MMESO AOR(s) they intend to submit quotes. Vendors will not have an opportunity to change MMESO AOR(s) during any subsequent stage in this evaluation. Phase II Clinical Performance Evaluation Following acceptability of the technical/company requirements, the MMESO Europe, on behalf of the CPT, will request product sample sets from the product group to be sent to the specific CPT members at the participating MTFs. Vendor will be given 30 calendar days from the issue of the notice in which to deliver the product samples for clinical evaluation in Phase II. Product samples must be shipped no later than fourteen (14) calendar days after issue of notice, and arrive at the designated addresses for each MTF by 5:00 PM local time before the 30th calendar day. Vendor must be able to deliver product literature, training materials and evaluation samples as requested to the MMESO Pacific via FedEx or UPS AND to the MMESO Europe via United States Postal Service (USPS) Express Mail AND throughout the United States by selected shipping method when requested in Phase II. Vendor must send the MMESO Europe verification regarding the shipment of literature and samples. This information will include the date of shipment, final delivery date, tracking numbers and the carrier used by the vendor. Vendor will provide only the following no cost product samples for clinical/performance evaluation. Unused samples will not be returned. One (1) of each splint roll with incorporated padding and five (5) of each precut splint with incorporated padding listed below are to be provided as samples to each of the evaluation sites as identified in the letters of invitation. 1) Fiberglass/synthetic splint roll with padding 4 inches wide by 15 feet long, one roll 2) Fiberglass/synthetic splint roll with padding 3 inches wide by 15 feet long, one roll 3) Fiberglass/synthetic splint pre-cut with padding 3 inches wide by 35 inches long, five splints 4) Fiberglass/synthetic splint pre-cut with padding 3 inches wide by 12 inches long, five splints Each evaluator will evaluate each product sample from each vendor against the established requirements. A trial will consist of evaluating sample products from a single vendor, evaluated against the requirements and recorded on a single evaluation form per vendor. Each evaluator will evaluate or trial each participating vendor's product line. The clinical/performance acceptability evaluation period will last for fourteen (14) calendar days. The acceptability evaluation responses will be in a Likert scale format with a one (1) through five (5) scoring range. The scale descriptors are: one (1) Completely Unacceptable, two (2) Overwhelmingly Unacceptable, three (3) Partially Unacceptable, four (4) Acceptable, and five (5) Highly Acceptable. The MMESO JPRB has established a 4.0 as the Clinically Preferred threshold of products for standardization. A vendor scoring below the clinically preferred threshold will be disqualified from selection for this standardization initiative. A vendor who has been disqualified will be notified in writing upon completion of the standardization selection. Of those vendors that are qualified as clinically preferred, selection will be based on best price. Clinical/performance acceptability evaluations by the participating CPT facilities will be tabulated resulting in one score per participating MMESO per vendor. The participating MMESOs' scores by vendor will then be combined resulting in one final vendor performance evaluation score. All clinical/performance acceptability evaluations will be tabulated by the MMESO Europe and results will be forwarded to the MMESO CPT for final review. There will be approximately twenty-one (21) MTFs enterprise wide that will be evaluating products. Clinical/Performance Requirements During the acquisition planning process, the CPT approved the clinical/performance acceptability requirements outlined below. 1. JC IC 01.02.01 - The splint material is moldable for precise fit providing the necessary support. The splint material must be moldable to allow for exact fit and smooth finish immobilizing the body part. 2. JC IC 01.02.01 - The application of the splinting material can be done with a wrinkle-free finish eliminating pressure points. The splinting material must be wrinkle-free. Wrinkles in materials cause pressure points which can cause skin breakdown leading to an infection and/or injury to the supported limb. 3. ASTM Standard F1536 - 95, 2010 - The splint material allows for vendor indicated set times. The splint material must set quickly, according to vendor specifications, to ensure the splinted limb is stabilized in the desired position. Phase III Pricing Analysis Upon completion of the Phase I - Technical/Company Requirements, a vendor who is found technically acceptable will be qualified / invited to provide product samples and price discount quotes concurrently. A vendor will be given 30 calendar days from the date of pricing requests to submit IA pricing quotes in a prescribed electronic spreadsheet format, based upon the requirements of the MMESOs. Pricing will be submitted to MMESO Europe and must be received by 5:00 PM EST, thirty (30) calendar days after the issue date of the vendor notice to submit best price quotes. Vendor quotes should contain the vendor's best product matches for the specific products requested in this announcement. Vendor quotes should contain the vendor's best discounts off of the vendor's DAPA pricing for the products identified in this announcement. Pricing should be provided for each MMESO AOR for which a quote is submitted based on a committed volume of 80% of the total volume in sales of the MTFs in that MMESO AOR. Vendor quotes will contain separate pricing for each MMESO AOR(s) for which a quote is submitted based on Technical / Company Requirements above. Vendor is not required to provide a quote for each MMESO AOR. Price will be analyzed based on the projected Aggregate Post-Standardization costs for each vendor. Aggregate Post-Standardization Cost will be calculated for each vendor by applying the vendor's offered prices to the anticipated annual usage of the enterprise. Unmatched items will be represented in the Post-Standardization Cost at a baseline non-discounted price (current DAPA price of product with highest procurement). Among the products and sources that are determined to be clinically preferred, the best price Aggregate Post-Standardization Cost will be selected for each MMESO AOR.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/DLA/J3/DSCP-M/ME-1111-08_Casting_Splints/listing.html)
- Place of Performance
- Address: ERMC HQ, CMR 442, Dept G4, Bldg 3613, Rm 0055, Heidelberg,Nachrichten Kaserne,, Non-U.S., APOAE09042, United States
- Zip Code: 09042
- Zip Code: 09042
- Record
- SN02745683-W 20120513/120511234819-be3cb17e4f641eb1a7ef350402cc1d27 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |